Blackhawk Capital Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.87M Buy
11,393
+600
+6% +$129K 0.94% 31
2026
Q1
$2.35M Sell
10,793
-118
-1% -$26.2K 0.86% 28
2025
Q4
$2.49M Sell
10,911
-187
-2% -$42.6K 0.94% 28
2025
Q3
$2.57M Sell
11,098
-100
-0.9% -$20.4K 1% 29
2025
Q2
$2.08M Buy
11,198
+5
+0% +$929 0.96% 33
2025
Q1
$2.35M Sell
11,193
-81
-0.7% -$15.7K 1.21% 25
2024
Q4
$2M Hold
11,274
1.04% 30
2024
Q3
$2.23M Hold
11,274
1.19% 27
2024
Q2
$1.93M Hold
11,274
1.17% 27
2024
Q1
$2.05M Sell
11,274
-60
-0.5% -$10.3K 1.28% 27
2023
Q4
$1.76M Hold
11,334
1.19% 32
2023
Q3
$1.69M Hold
11,334
1.24% 32
2023
Q2
$1.53M Hold
11,334
1.06% 39
2023
Q1
$1.81M Sell
11,334
-114
-1% -$17.4K 1.32% 29
2022
Q4
$1.85M Sell
11,448
-2,175
-16% -$333K 1.45% 24
2022
Q3
$1.83M Hold
13,623
1.51% 20
2022
Q2
$2.09M Buy
13,623
+9,223
+210% +$1.41M 1.63% 20
2022
Q1
$713K Sell
4,400
-18,109
-80% -$2.63M 0.48% 64
2021
Q4
$3.05M Buy
22,509
+463
+2% +$54.7K 1.84% 14
2021
Q3
$2.38M Buy
22,046
+2,839
+15% +$324K 1.5% 17
2021
Q2
$2.08M Buy
19,207
+467
+2% +$52.6K 1.41% 22
2021
Q1
$2.01M Sell
18,740
-29
-0.2% -$3.1K 1.51% 17
2020
Q4
$1.64M Buy
18,769
+1,031
+6% +$99.1K 1.41% 24
2020
Q3
$1.74M Sell
17,738
-7,318
-29% -$689K 1.58% 20
2020
Q2
$1.91M Sell
25,056
-1,739
-6% -$153K 2.28% 13
2020
Q1
$2.37M Sell
26,795
-2,804
-9% -$239K 2.12% 15
2019
Q4
$2.24M Hold
29,599
2.23% 10
2019
Q3
$2.24M Buy
29,599
+3,295
+13% +$226K 2.1% 11
2019
Q2
$1.91M Buy
26,304
+5,554
+27% +$437K 1.83% 19
2019
Q1
$1.67M Buy
20,750
+8,823
+74% +$722K 1.73% 18
2018
Q4
$1.1M Buy
11,927
+8,229
+223% +$724K 1.4% 32
2018
Q3
$350K Hold
3,698
0.49% 47
2018
Q2
$343K Buy
3,698
+149
+4% +$14.6K 0.39% 67
2018
Q1
$336K Sell
3,549
-357
-9% -$39.2K 0.29% 73
2017
Q4
$378K Buy
+3,906
New +$368K 0.33% 73

Other funds holding ABBV

Blackhawk Capital Partners's ABBV Position: Q2 2026 in Review

Blackhawk Capital Partners increased its AbbVie (ABBV) stake by 5.6% in Q2 2026, buying an estimated $129K and bringing the position to 11,393 shares worth $2.87M. The position accounts for 0.94% of the portfolio, ranked #31.

Blackhawk Capital Partners first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.05M in Q4 2021. 1,503 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Blackhawk Capital Partners held 11,393 shares of AbbVie worth $2.87M as of Q2 2026.
  • Blackhawk Capital Partners bought 600 AbbVie shares in Q2 2026, an estimated $129K.
  • AbbVie made up 0.94% of Blackhawk Capital Partners's portfolio in Q2 2026, its #31 holding.
  • Blackhawk Capital Partners first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
  • Blackhawk Capital Partners's AbbVie position peaked at $3.05M in Q4 2021.
  • 1,503 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Blackhawk Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.